Please select the option that best describes you:
Would you consider addition of docetaxel to abiraterone and ADT in metastatic hormone senstive prostate cancer patients who progress on ADT and abiraterone?
Would the results of PEACE-1 trial justify this?
Answer from: Medical Oncologist at Community Practice
The question is incorrectly phrased, when a patient progresses on ADT and Abi they are not hormone sensitive.
In patients with high risk metastatic prostate cancer, I would not add docetaxel to abi and ADT yet as OS data has not matured. However, I do sequence them in a select group of high risk pa...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The data from the PEACE-1 trial may end up helping to set a new standard for mHSPC and demonstrating safety of combination docetaxel with abiraterone, but if the question is whether or not to continue abiraterone in the setting of progression when starting docetaxel for mCRPC, PEACE-1 probably isn't...